Auxilium Pharmaceuticals — Investor Presentation (September 2009)
56 slides from Auxilium Pharmaceuticals's investor presentation, Sep 21, 2009
Slide 1: Auxilium Pharmaceuticals Investor Presentation, September 2009
September 2009 Exhibit 99.1 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 4: 2009 Milestones Achieved
• Completed enrollment in Peyronie’s Phase IIb (Feb. 2) • Filed BLA for Dupuytren's Contracture (Feb. 27) • Received FDA priority review (Apr. 28) and PDUFA Date (Aug. 28) • Secured $30 M Revolving Credit Line with Silicon Valley Bank (Aug. 4) • CORD I published in New England Journal of Medicine (S
Slide 5: Anticipated XIAFLEX Events
• U.S. Dupuytren’s Contracture Launch (~ 60 days post-approval) • Top-line results of Peyronie's Phase IIb Study (Dec 09) • Pfizer files MAA for Dupuytren’s Contracture in EU (2010) • Initiation of Peyronie's Phase III Studies (2010) Anticipated XIAFLEX Events 2009 2010 Timing Dupuytren’s Peyronie’s
Slide 6: Pipeline Continues to Advance
Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy
Slide 7: XIAFLEX Driver of Long-Term Growth
XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA
Slide 8: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener
Slide 9: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese
Slide 10: Current Treatment Options Require Invasive Surgery or Are Unapproved
Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 11: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea
Slide 12: CORD I - Largest Double-blind, Placebo-controlled Trial
CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture • Primary endpoint is reduction in contracture to within - of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Seconda
Slide 13: Results Are Comparable to Surgery at the Joint Level
Results Are Comparable to Surgery at the Joint Level Hurst et al. NEJM 2009 Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) P < 0.001 P < 0.001 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) P < 0.001 MP = metacarpophal
Slide 14: Almost 100% of MP Joints and 2/3 of PIP Joints Improved Over 50%
Almost 100% of MP Joints and 2/3 of PIP Joints Achieved Better than 50% Improvement Hurst et al. NEJM 2009 MP = metacarpophalangeal PIP = proximal interphalangeal 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) 100%
Slide 15: MP Joints Responded Better than PIP Joints
MP Joints Responded Better than PIP Joints, but PIP Joints Were More Severe at Baseline Hurst et al. NEJM 2009 79.3% reduction in contracture for XIAFLEX patients vs. 8.6% reduction for placebo patients (p<0.001) Baseline Last XIAFLEX (All Joints) (N=203) Placebo (N=103) MP Joints (N=133) PIP Joints
Slide 16: Greater Improvement in Range of Motion than Placebo
Treatment with XIAFLEX Resulted in Greater Improvement in Range of Motion than Treatment with Placebo 36.7 vs 4 P < 0.001 Hurst et al. NEJM 2009 36.7 43.9 80.7 49.5 45.3 Collagenase Placebo ° ° ° ° ° °
Slide 17: MP Joints Exhibited a 41º Mean Improvement in Range of Motion
MP Joints Treated with XIAFLEX Exhibited a 41º Mean Improvement in Range of Motion Baseline 30 Days After Last Injection Mean values were rounded to the nearest whole number. Hurst et al. NEJM 2009
Slide 18: PIP Joints Mean Improvement in Range of Motion
PIP Joints Treated with XIAFLEX Exhibited a 29 Mean Improvement in Range of Motion Baseline 30 Days After Last Injection Mean values were rounded to the nearest whole number. Hurst et al. NEJM 2009 °
Slide 19: Early Intervention with XIAFLEX May Be Most Effective
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach MP Joints PIP Joints MP = metacarpophalangeal PIP = proximal interphalangeal Hurst et al. NEJM 2009 88.9% (72/81) 57.7% (30/52) Less Severe More Severe 80.9% (17/21) 22.4% (11/49) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Slide 20: XIAFLEX Was Well-Tolerated in the CORD I Study
XIAFLEX Was Well-Tolerated in the CORD I Study • The overwhelming majority of adverse events were local reactions and rates were consistent with prior XIAFLEX trials • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 day
Slide 21: XIAFLEX is a Potential First-line Nonsurgical Option
XIAFLEX is a Potential, First-line Nonsurgical Option for Patients with Dupuytren’s Contracture • Efficacy should compare favorably to surgery – Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake
Slide 22: Phase III AE and SAE Rates Compare Favorably to Surgical Complications
XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Tendonitis 1 0.04% Boutonniere Deformity 1 0.04% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Sensory
Slide 23: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture
Slide 24: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in
Slide 25: XIAFLEX Supply Chain
XIAFLEX Supply Chain • API produced in Horsham, PA – 2 ° - 8 ° C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophiliza
Slide 26: Dupuytren's Contracture – an Unmet Medical Need
Dupuytren’s Contracture –an Unmet Medical Need NEJM 2009 Hueston 1963 Skoog 1948 Mikkelsen 1976 Tubiana • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to Million, in U.S. and EU, but occurs in all populations • Higher prevalence in patients of northern-European des
Slide 27: Long-term Observational Follow-up Study
AUX-CC-860 is a 2 to 5 Year Long-term Observational Follow-up Study • To assess the durability of response in joints with measurable improvement ( 20 ° ) in contracture after treatment with AA4500 • To assess the progression of disease • In joints that were not treated, or • Did not have measurable
Slide 28: XIAFLEX Risk Management Plan
XIAFLEX Risk Management Plan Goal Is to Ensure Appropriate Administration • Recognize potential and identified risks – Potential: Injection related bleeding due to coagulation disorder, allergic reactions – Identified: localized reactions and tendon ruptures • Creation and implementation of strategi
Slide 29: Access Management Program Training
Access Management Program Training Would Be Required To Access XIAFLEX Focus on physicians experienced in the diagnosis and management of Dupuytren’s Disease: • Hand surgeons, orthopedic surgeons, plastic surgeons, general surgeons (hand focus) and rheumatologists • Must attest to completion of the
Slide 30: Access Management Program Designed to Support Appropriate Physician Usage
Access Management Program Designed to Support Appropriate Physician Usage Distributor checks enrollment database Doctor wants to use AA4500 Contacts Distributor Distributor ships AA4500 Redirects physician to web site for enrollment information Physician Training Program (Web site, Video, or Manual)
Slide 31: Extensive Market Research with Dupuytren's Surgeons
Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo
Slide 32: Annually, >240,000 Dupuytren's Candidates Between U.S. & EU
Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis
Slide 33: Sustainable Blockbuster Market for Dupuytren's Contracture
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence • Sustainable patient pool – New patients within an ageing population • Average of 2.2 joints affected at time of diagnosis • ~ 50% of patients have bilateral disease – Disease progression to additional
Slide 34: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/ d
Slide 35: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith
Slide 36: Current Surgical Options - Treatment of Last Resort
Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att
Slide 37: Unapproved Treatments for Peyronie's Disease
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 38: Study 1030 / Study 1035
Study 1030 Percent of patients a-i-a- Month 3 Month 6 Month 9 Study 1035 Lia : | Week6 Month3 Month6 Months Ux IUM | Innovations for Lite™
Slide 39: Peyronie's Phase IIb Study Top-line Data Expected December 2009
Peyronie’s Phase IIb Study Top-line Data Expected in December 2009 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to main
Slide 40: Peyronie's Phase IIb Study Design
Peyronie’s Phase IIb Study Design A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 Arm Study Drug Plaque Modeling Targeted Number of Patients • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.
Slide 41: Phase IIb Trial Utilizes a Novel Patient Reported Outcome
Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro
Slide 42: Extensive Market Research with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe
Slide 43: Annually, >210,000 Peyronie's Candidates Between U.S. and Europe
Annually, >210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis
Slide 44: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F
Slide 45: Strong Strategic Partner for XIAFLEX in EU
Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pf
Slide 46: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver
Slide 47: Testim Maintains Double-Digit Growth in TRT Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad
Slide 48: Patient Results Were Proven in Clinical Studies
Patient Results Were Proven in Clinical Studies Total Testosterone Free Testosterone Note: Adjusted geometric means (CV b %) of a single-dose (50 mg testosterone), randomized, complete crossover study of 29 hypogonadal men. 2,000 3,000 4,000 5,000 6,000 Mean AUC 0-24 (ng*h/dL) Testim AndroGel Mean A
Slide 49: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) July 2009 L12M: 26.4%
Slide 50: Testim Quarterly Net Revenues and Scripts
Testim® Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth ($ in millions) 2Q09 Net Testim Revenues Y/Y Growth: +26.8% 2Q09 TRX Y/Y Growth: +15.7% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.1M $72.1M
Slide 51: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t
Slide 52: FDA Has Granted Our Citizen's Petition In Part
FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers
Slide 53: 1H '09 Financial Results and 2009 Guidance
Revenues $73.9 $58.0 $155-165 R&D Expense $27.2 $26.6 $45-50 SG&A Expense $55.8 $43.2 $120-130 Net Loss ($26.6) ($25.2) ($50-55) Stock – Based Comp Expense $9.4 $4.9 $16-19 Cash & Cash Equivalents $80.4 1H ‘09 Financial Results and 2009 Guidance ($ Millions) 1H ’09 1H ‘08 Guidance Currently approxim
Slide 54: Strategic Priorities in 2009 and 2010
Strategic Priorities in 2009 and 2010 • Obtain approval from the FDA in Dupuytren’s Contracture; • Execute a successful launch in the U.S. for XIAFLEX in Dupuytren’s contracture approximately 60 days after our approval date; • Complete enrollment in the observational long term follow up study of Dup
Slide 55: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 56: Auxilium Management Contact
Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 [email protected] William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 [email protected] September 2009 (NASDAQ: AUXL)
Auxilium Pharmaceuticals — Investor Presentation (September 2009) on 6ix